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Abstract In G protein-coupled receptors, a NP(X)nY motif in
the seventh transmembrane domain and cysteine residues in the
C-terminal juxtamembrane region are conserved. In the current
study, the roles of Y299 within the NPVIY motif and C313 and
C320 in the C-terminal juxtamembrane region of the human CB2
cannabinoid receptor were investigated by site-directed mutagen-
esis. Replacing Y299 with alanine resulted in a complete loss of
ligand binding and a severe impairment of cannabinoid-induced
inhibition of forskolin-stimulated cAMP accumulation. The
C313A and C320A mutations markedly reduced functional
coupling to adenylate cyclase, but had no effect on ligand
binding and agonist-induced receptor desensitization. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: Cannabinoid receptor 2; Cannabinoid; Site-
directed mutagenesis; Structure; Function
1. Introduction
To date, two types of cannabinoid receptors, CB1 and CB2,
have been cloned [1,2]. CB2 exhibits 44% amino acid identity
with CB1 [2]. CB1 is located in the central nervous system as
well as in peripheral tissues [1,3,4]. CB2 is distributed primar-
ily in peripheral tissues such as immune cells [2,3]. It is known
that activation of both CB1 and CB2 cannabinoid receptors
inhibits adenylate cyclase through coupling with pertussis tox-
in-sensitive G proteins [5,6]. However, currently very little
information is available regarding the molecular mechanisms
for the activation of these receptors. Studying the structure
and function of CB2 has potential therapeutic implications.
Since CB2 is not located in the central nervous system, ligands
that selectively activate CB2 would be devoid of the psycho-
active e¡ects of marijuana.
Cannabinoid receptors belong to the G protein-coupled re-
ceptor (GPCR) superfamily [7^9]. These receptors contain
seven putative transmembrane domains connected by three
extracellular and three intracellular loops. In general, the
extracellular loops and/or transmembrane regions are in-
volved in ligand binding, whereas cytoplasmic regions contain
sites for interactions with G proteins [10,11]. In many GPCRs,
a NP(X)nY motif within the seventh transmembrane domain
(TM7) near the cytoplasmic face of the plasma membrane is
highly conserved. This sequence has been postulated to play
important roles in receptor activation and regulation [12^15].
The NP(X)nY motif exists in TM7 of the CB2 receptor as
NPVIY, with the Y being Y299 (Fig. 1). Furthermore, most
GPCRs have one or two conserved cysteine(s) in the C-termi-
nal juxtamembrane region. These cysteines are sites for pal-
mitoylation, which has been suggested to play important roles
for receptor^G protein coupling and receptor desensitization
[15^18]. In the CB2 receptor, two cysteines, C313 and C320,
are located in the C-terminal juxtamembrane region (Fig. 1).
The Y in the NP(X)nY motif and the cysteines in the C-
terminal juxtamembrane region of GPCRs have been shown
to play important roles in functional coupling and desensiti-
zation of these receptors [12^18]. Based on these previous
¢ndings, our hypothesis is that Y299 in the NPVIY motif
and C313 and C320 in the C-terminal juxtamembrane region
of the CB2 receptor may be crucial for the activation and
desensitization of this receptor. To test this hypothesis,
Y299, C313, and C320 of the CB2 receptor were mutated to
alanine in this study. These mutant receptors were stably
transfected into human embryonic kidney 293 (HEK293) cells
and their ligand binding, signal transduction, and desensitiza-
tion properties were compared with those of the wild-type
CB2 receptor.
2. Materials and methods
2.1. Materials
Enzymes and reagents used for recombinant DNA experiments
were purchased from Gibco-BRL (Gaithersburg, MD, USA) or
Promega (Madison, WI, USA). Adenovirus-transformed HEK293
cells were obtained from American Type Culture Collection (Rock-
ville, MD, USA). Dulbecco’s modi¢ed Eagle’s medium (DMEM),
fetal bovine serum, penicillin/streptomycin, L-glutamine, trypsin and
Geneticin were purchased from Biowhittaker (Walkersville, MD,
USA). Anandamide and WIN55212-2 were obtained from RBI (Ba-
tick, MA, USA). HU-210 and [3H]HU-243 were obtained from Tocris
(Ballwin, MO, USA). [125I]Cyclic AMP used for radioimmunoassays
was purchased from New England Nuclear (Boston, MA, USA).
2.2. Mutagenesis
A 1.8-kb full-length human CB2 cDNA was subcloned into pRC/
CMV (Invitrogen, San Diego, CA, USA) to construct the expression
plasmid pHCB2-RC/CMV [19]. The GeneEditor in vitro site-directed
mutagenesis system (Promega, Madison, WI, USA) was used to mu-
tate the CB2 receptor. The following oligonucleotides were used:
Y299A, 5P-AACCCTGTCATCGCTGCTCTACGGAG-3P ; C313A,
5P-CTCTGCCCATCACGC-CCTGGCTCACTGG-3P ; C320A, 5P-T-
CACTGGAAGAAGGCTGTGAGGGGCCTTG-3P. The presence of
the mutation as well as the accuracy of the DNA sequences was
con¢rmed by dideoxy sequencing.
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2.3. Cell transfection and culture
Expression plasmids containing wild-type and mutant CB2 recep-
tors were transfected into HEK293 cells. Transfected cells were se-
lected in culture medium containing 500 Wg/ml Geneticin, and cell
lines stably expressing wild-type and mutant cannabinoid receptors
were established according to a previously established method [20].
Cells were grown as monolayers in DMEM containing 10% fetal
bovine serum, 2 mM glutamine, 100 U/ml penicillin, 100 Wg/ml strep-
tomycin and 400 Wg/ml Geneticin in a humidi¢ed atmosphere consist-
ing of 5% CO2 and 95% air, at 37‡C.
2.4. Immuno£uorescence staining
HEK293 cells stably expressing wild-type and mutant CB2 recep-
tors were grown on cover glass. Cells were washed twice with 0.1 M
phosphate-bu¡ered saline (PBS), pH 7.4, ¢xed with 4% paraformal-
dehyde for 15 min, and washed twice with PBS for 5 min each time.
The cells were incubated with PBS containing 5% normal goat serum
(NGS) at room temperature for 1 h, and then incubated with the anti-
CB2 antibody (Cayman, Ann Arbor, MI, USA) at room temperature
for 2 h. After washing three times with PBS containing 5% NGS for
10 min each time, cells were incubated with £uorescein isothiocyanate-
conjugated anti-rabbit IgG (Zymed, San Francisco, CA, USA) at
room temperature for 1 h. After washing four times with PBS, cover-
slips were mounted with Vectashield (Vector Laboratories, Burlin-
game, CA, USA) and viewed with an Olympus IX50 £uorescence
microscope.
2.5. Ligand binding and cAMP accumulation assays
Ligand binding assays were performed as previously described
[19,21]. Brie£y, the cells were homogenized in membrane bu¡er (50
mM Tris^HCl, 5 mM MgCl2, 2.5 mM EDTA, pH 7.4) and cell mem-
branes were obtained by centrifugation at 32 000Ug for 20 min. Mem-
brane protein concentrations were determined by the use of a bicin-
choninic acid protein reagent kit (Pierce, Rockford, IL, USA).
Membranes were incubated with 0.2 nM [3H]HU-243 and di¡erent
concentrations of unlabeled ligands at 30‡C for 60 min. Non-speci¢c
binding was determined in the presence of 0.1 WM unlabeled HU-210.
Free and bound radioligands were separated by rapid ¢ltration
through polyethyleneimine-treated GF/B ¢lters (Whatman Interna-
tional, Maidstone, UK). The ¢lters were washed three times with
3 ml of cold 50 mM Tris^HCl, pH 7.4, and bound radioactivity
was determined by liquid scintillation counting.
cAMP accumulation assays were performed using a previously pub-
lished method [19,21]. Brie£y, cannabinoid ligands in di¡erent con-
centrations were mixed with forskolin. Con£uent cells were lifted and
incubated with phosphodiesterase inhibitor RO20-1724 (Biomol, Ply-
mouth Meeting, PA, USA) for 10 min. The stimulation was initiated
by adding cells to the test tubes containing forskolin and cannabi-
noids, and incubated for 5 min at 37‡C. The reaction was stopped
with the addition of 0.1 N HCl, after which 50 Wl was removed for
cAMP radioimmunoassay, using a kit from DuPont-NEN (Wilming-
ton, DE, USA).
2.6. Desensitization experiments
To study receptor desensitization, cells were pretreated in DMEM
containing 0.2% bovine serum albumin and 3 nM HU-210 at 37‡C for
1 h. Subsequently, cAMP accumulation assays were performed as
described in Section 2.5.
2.7. Data analysis
Data from ligand binding and cAMP accumulation assays were
analyzed, and curves were generated with use of the Prizm program
(GraphPad Software, San Diego, CA, USA). IC50 and EC50 values
were determined through non-linear regression analysis performed
with the Prizm program. Kd and Bmax values were estimated from
competition binding experiments with the following equations:
Kd = IC503L and Bmax = (B0IC50)/L, where L is the concentration of
free radioligand, and B0 is speci¢cally bound radioligand [22]. The Ki
values were calculated based on the Cheng^Pruso¡ equation:
Ki = IC50/(1+L/Kd) [23].
3. Results
3.1. Expression of wild-type and mutant CB2 receptors
Immuno£uorescent microscopy study was performed to ex-
amine the expression of wild-type and mutant CB2 receptors.
Using the anti-CB2 antibody, which is directed against the
extracellular N-terminal of CB2 receptor, positive immuno-
£uorescence staining signals were observed in non-permeabi-
lized HEK293 cells stably transfected with Y299A, C313A,
and C320A, as well as wild-type CB2 receptors (Fig. 2). The
results indicate that these receptors were properly targeted
into the plasma membranes.
Table 1
The ligand binding parameters of the wild-type and mutant CB2 receptors
Wild-type C313A C320A
Bmax, fmol/mg protein 2846.9 þ 837.9 2782.4 þ 458.9 2502.2 þ 415.7
HU-210 Kd/Ki, nM 0.47 þ 0.06 0.39 þ 0.11 0.23 þ 0.06
WIN55212^2 Kd/Ki, nM 3.4 þ 1.0 3.1 þ 0.4 6.5 þ 0.7
Anandamide Kd/Ki, nM 314.5 þ 64.8 448.4 þ 48.5 234.1 þ 31.9
Competition assays were performed on membranes prepared from cells expressing wild-type, C313A, and C320A mutant CB2 receptors using
[3H]HU-243 as radioligand. Values are shown as mean þ S.E.M. of at least three independent experiments, each performed in duplicate.
Fig. 1. Schematic depiction of the CB2 cannabinoid receptor mem-
brane topology and the location of Y299, C313 and C320.
Fig. 2. Immuno£uorescent staining of HEK293 cells stably trans-
fected with the wild-type and mutant CB2 cannabinoid receptors.
A: Wild-type CB2 receptor. B: Y299A mutant. C: C313A mutant.
D: C320A mutant.
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3.2. Ligand binding
Fig. 3 and Table 1 show the ligand binding curves and
parameters of wild-type and mutant CB2 receptors. The
wild-type CB2 receptor displayed high a⁄nity binding of
[3H]HU-243 with a Kd of 0.47 þ 0.06 nM and a Bmax of
2846.9 þ 837.9 fmol/mg of membrane protein. While no spe-
ci¢c binding was detected with the Y299A mutant receptor,
speci¢c and high a⁄nity binding of [3H]HU-243 was found
with C313A and C320A mutant receptors. For the wild-type
CB2 receptor, the rank order of potency for three structurally
distinct cannabinoid ligands to compete for the binding of
[3H]HU-243 was HU-210sWIN55212^2s anandamide. For
the C313A and C320A mutant receptors, HU-210,
WIN55212-2, and anandamide had ligand binding a⁄nities
similar to those for the wild-type CB2 receptor, and the
rank order of potency for the three ligands to compete for
the binding of [3H]HU-243 was the same as that for wild-type
CB2 receptor. Furthermore, the Bmax values of neither C313A
nor C320A mutant receptors are signi¢cantly di¡erent from
that of the wild-type CB2 receptor (Ps 0.05).
3.3. Coupling to adenylate cyclase
To compare the signaling properties of C313A and C320A
mutant receptors with that of wild-type CB2 receptor, the
ability of cannabinoid agonists to inhibit forskolin-stimulated
cAMP accumulation was determined in HEK293 cells stably
transfected with these receptors. As shown in Fig. 4, in cells
expressing wild-type CB2 receptor, three cannabinoid agonists
inhibited forskolin-stimulated cAMP accumulation in a con-
Fig. 3. Comparison of the wild-type and mutant CB2 receptors for
cannabinoid ligand binding. Three cannabinoid ligands, HU-210
(A), WIN55212-2 (B), and anandamide (C), were used for ligand
binding experiments using membranes prepared from HEK293 cells
stably expressing the wild-type (F), Y299A (R), C313A (b) and
C320A (8) mutant CB2 receptors. [3H]HU-243 speci¢c binding in
the absence of unlabeled ligand was de¢ned as 100%. Data shown
represent the mean þ S.E.M. of at least three independent experi-
ments performed in duplicate. Curves were generated as described
in Section 2.
Fig. 4. Comparison of the wild-type and mutant CB2 receptors for
agonist-induced inhibition of forskolin-stimulated cAMP accumula-
tion. Three cannabinoid ligands, HU210 (A), WIN55212-2 (B), and
anandamide (C), were used for cAMP accumulation assay using
HEK293 cells stably expressing wild-type (F), Y299A (R), C313A
(b) and C320A (8) mutant CB2 receptors. The forskolin-stimulated
cAMP accumulation in the absence of cannabinoid ligands
(6.83 þ 0.24 pmol/105 cells) was de¢ned as 100%. Data shown repre-
sent the mean þ S.E.M. of at least three independent experiments
performed in triplicate. Curves were generated as described in Sec-
tion 2.
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centration-dependent manner. The rank order of potency was
HU-210sWIN55212-2s anandamide. The maximum inhibi-
tion of forskolin-stimulated cAMP accumulation was
63.3 þ 2.1% by HU-210, 54.1 þ 4.4% by WIN55212-2, and
30.2 þ 4.8% by anandamide. At the highest concentrations
used on transfected cells, none of these cannabinoid agonists
inhibited cAMP accumulation in untransfected cells (data not
shown). Thus, all of the inhibition of cAMP accumulation
shown is receptor-mediated.
In HEK293 cells stably transfected with Y299A, C313A,
and C320A mutant receptors, the ability of HU-210 and
WIN55212-2 to inhibit forskolin-stimulated cAMP accumula-
tion was severely impaired, and the e¡ect of anandamide was
completely abolished (Fig. 4).
3.4. Receptor desensitization
To study agonist-induced desensitization of adenylate cy-
clase responses, HEK293 cells expressing wild-type and
C313A and C320A mutant CB2 receptors were pretreated
with 3 nM HU-210 for 1 h before the cAMP accumulation
assay. As shown in Fig. 5, for wild-type CB2 receptor, HU-
210 pretreatment markedly decreased the ability of HU-210 to
inhibit forskolin-stimulated cAMP accumulation, with a 76%
(from 63.3 þ 2.1% to 15.2 þ 5.0%) decrease of maximum inhi-
bition by HU-210. For C313A and C320A mutants, the max-
imum inhibition by HU-210 was decreased by 72% (from
30.7 þ 11.5% to 8.5 þ 4.1%) and 76% (from 48.7 þ 15.0% to
11.5 þ 4.8%), respectively, due to HU-210 pretreatment.
Therefore, in cells expressing C313A and C320A mutant re-
ceptors, the maximum inhibition by HU-210 was decreased by
a similar extent as the wild-type CB2 receptor due to HU-210
pretreatment-induced receptor desensitization.
4. Discussion
4.1. Roles of Y299 in ligand binding and coupling to adenylate
cyclase
In this study we hypothesized that conserved Y299 in the
TM7 NPVIY motif of the CB2 receptor might be important
for ligand binding and functional coupling. To test our hy-
pothesis, the Y299A mutation was made and examined. This
mutation produced a receptor that was correctly targeted into
the plasma membrane. However, this mutation led to a com-
plete loss of ligand binding and a severe impairment of func-
tional coupling to adenylate cyclase. These data indicate a
critical role of Y299 in ligand binding and functional coupling
of the CB2 receptor. Since the location of Y299 is very close
to the cytoplasmic face of the plasma membrane, this amino
acid is unlikely to be involved directly in ligand binding.
Therefore, the loss of ligand binding caused by Y299A muta-
tion is most likely due to indirect, conformational changes.
Our results on Y299A mutation are in agreement with those
of the studies on L2-adrenoceptor [13] and human somatostat-
in receptor type 5 [15]. These studies also demonstrated a
severe loss of ligand binding when the tyrosine residue in
the NP(X)nY motif was mutated to alanine. However, our
data are di¡erent from the studies with human angiotensin
II type 1 receptor [12] and K1B-adrenergic receptor [14]. In
these studies, the tyrosine residue in the NP(X)nY motif has
been shown to be important for functional coupling, but not
for ligand binding. Taken together, this suggests that the roles
of tyrosine in the NP(X)nY motif are receptor-speci¢c.
4.2. Roles of C313 and C320 in ligand binding, coupling to
adenylate cyclase, and receptor desensitization
Experiments were performed in this study to test our hy-
pothesis that two cysteine residues in the C-terminal juxta-
membrane region of the CB2 receptor may be important for
its function. Our data showed that mutating C313 and C320
to alanine in the CB2 receptor gave correctly expressed recep-
tor protein and had no e¡ect on ligand binding. These results
indicate that these two cysteines of the CB2 receptor are not
crucial for receptor expression or ligand binding. However, in
HEK293 cells expressing C313A and C320A mutant recep-
tors, agonist-induced inhibition of forskolin-stimulated
cAMP accumulation was severely impaired. These data dem-
onstrate that these two cysteine residues in the C-terminal
juxtamembrane region of the CB2 receptor have critical roles
in negatively coupling to adenylate cyclase. In addition, our
Fig. 5. Agonist-induced desensitization of the wild-type (A), C313A
(B), and C320A (C) mutant CB2 receptors. Cells were pretreated
with 3 nM HU-210 (E) or vehicle (F) for 1 h. The forskolin-stimu-
lated cAMP accumulation in the absence of cannabinoid ligands
was de¢ned as 100%. Data shown represent the mean þ S.E.M. of at
least three independent experiments performed in triplicate. Curves
were generated as described in Section 2.
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desensitization experiments showed that the C313A and
C320A mutations had no e¡ects on agonist-induced receptor
desensitization.
Our observation on the ligand binding properties of C313A
and C320A mutant receptors is in agreement with those of
several other GPCRs, which also indicated that the conserved
cysteines in the C-terminal juxtamembrane region are not
crucial for ligand binding [15,18]. Regarding the roles of these
cysteines in functional coupling, our data are consistent with
those obtained with human L2-adrenergic receptor [16], which
also showed a critical role of these cysteines for functional
coupling. However, our results di¡er from several other
GPCRs, such as, human somatostatin receptor type 5 [15]
and K2A-adrenergic receptor [17], in which the conserved cys-
teines are not crucial for functional coupling. Furthermore,
we demonstrated that the C313 and C320 are not essential
for agonist-induced receptor desensitization in the CB2 recep-
tor. This ¢nding is in contrast to the previous reports on
human somatostatin receptor type 5 [15] and glucose-depen-
dent insulinotropic peptide receptor [18], which have shown
that the conserved cysteine residues are crucial for receptor
desensitization. It remains to be studied why the conserved C-
terminal juxtamembrane region cysteines play di¡erent roles
among di¡erent GPCRs.
In summary, we have shown that the Y299 in the TM7
NPVIY motif of the CB2 receptor is critical for ligand binding
and functionally coupling to adenylate cyclase. We have also
demonstrated that C313 and C320 at the C-terminal juxta-
membrane region of the CB2 receptor is critical for coupling
to adenylate cyclase, but not for ligand binding and receptor
desensitization.
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